Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib and Nivolumab in Advanced nccRCC
NCT06053658Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Nov 2028
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib in non-clear cell renal cell carcinoma (nccRCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2024; status: recruiting.
02
Drugs
tivozanib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT06053658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053658.